NRXP
NRX Pharmaceuticals, Inc.Company Information
- Company Name
- NRX Pharmaceuticals, Inc.
- CIK
- CIK0001719406
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- NRXP: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- NRXP
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-12-17
- Last sale
- 2022-12-07
- Shares purchased (TTM)
- 40,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 11,521,371
- Shares outstanding
- 37,649,382
- Ownership
- 30.60%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- 6.73%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series Convertible Preferred Stock | - | - | - | - | - | - | - | - | - | 12 | 3 | 12 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 29 | 7 | 9 | 12 | 5 | 7 | 3 | 4 | 5 | 3 | 7 | 13 | ||||||
| Cash And Cash Equivalents At Carrying Value | 27 | 7 | 8 | 7 | 3 | 6 | 1 | 2 | 2 | 1 | 5 | 9 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 2 | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 4 | ||||||
| Equity Method Investments | 0 | 0 | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Property Plant And Equipment Net | 1 | 0 | 0 | 0 | - | - | 0 | - | - | - | - | - | ||||||
| Operating Lease Right Of Use Asset | - | - | - | 0 | - | - | - | - | - | - | - | - | ||||||
| Intangible Assets Net Excluding Goodwill | 1 | 1 | 1 | 2 | - | - | 0 | - | - | - | - | - | ||||||
| Goodwill | 2 | 2 | 2 | 1 | - | - | 0 | - | - | - | - | - | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 34 | 12 | 13 | 15 | 5 | 8 | 4 | 4 | 5 | 4 | 7 | 13 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 6 | 5 | 4 | ||||||
| Accrued Liabilities Current | - | - | - | - | - | - | - | - | - | 5 | 5 | 5 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 34 | 25 | 29 | 41 | 40 | 33 | 22 | 20 | - | - | 19 | 19 | ||||||
| Convertible Notes Payable | - | - | - | - | - | - | - | - | 8 | - | - | - | ||||||
| Convertible Notes Payable Current | - | - | 0 | 10 | 10 | 8 | 1 | 3 | - | - | 9 | - | ||||||
| Loans Payable Current | 0 | - | 0 | 0 | 0 | 0 | 0 | 1 | 1 | - | 0 | - | ||||||
| Derivative Liabilities | - | - | - | - | - | - | - | - | 0 | - | - | - | ||||||
| Derivative Liabilities Current | 19 | 9 | 12 | 16 | 16 | 10 | 6 | 2 | - | 0 | 0 | 0 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | - | - | - | - | 0 | 0 | -0 | -0 | -0 | -0 | ||||||
| Convertible Long Term Notes Payable | - | - | 0 | 0 | 0 | 0 | 5 | 3 | - | - | 0 | - | ||||||
| Liabilities | 34 | 26 | 29 | 41 | 40 | 33 | 27 | 23 | 24 | 19 | 19 | 19 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | -0 | -14 | -16 | -26 | -36 | -25 | -23 | -19 | -18 | -15 | -12 | -6 | ||||||
| Additional Paid In Capital | 325 | 294 | 291 | 281 | 266 | 259 | 255 | 250 | 249 | 245 | 241 | 243 | ||||||
| Retained Earnings Accumulated Deficit | -325 | -308 | -307 | -307 | -301 | -284 | -278 | -269 | -268 | -260 | -253 | -249 | ||||||
| Liabilities And Stockholders Equity | 34 | 12 | 13 | 15 | 5 | 8 | 4 | 4 | 5 | 4 | 7 | 13 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 43 | 33 | 32 | 28 | 19 | 17 | 15 | 11 | 11 | 96 | 8 | 8 | ||||||
| Shares Outstanding | 43 | 33 | 32 | 28 | 19 | 17 | 15 | 11 | 11 | 96 | 8 | 8 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialNRX Pharmaceuticals, Inc. (NRXP) — SEC Financial Statements & Analysis
NRX Pharmaceuticals, Inc. (NRXP) is a pharmaceutical preparations company, incorporated in DE. NRX Pharmaceuticals, Inc. trades on Nasdaq as: NRXP. NRX Pharmaceuticals, Inc. (NRXP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, NRX Pharmaceuticals, Inc. carries a market cap of $153.99M, a P/E ratio of -6.56x, a P/B ratio of -905.80x, a P/S ratio of 45.37x, an enterprise value of $127.71M, and an EV/EBITDA multiple of -6.49x. On profitability, it posts a gross margin of 46.64%, an operating margin of -586.15%, a net margin of -691.78%, a Return on Equity (ROE) of 131.22%, and a Return on Assets (ROA) of -120.41%. Per share, it reports EPS of $-0.62, diluted EPS of $-2.90, free cash flow per share of $-0.62, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -30.52% year-over-year and EPS growth of -66.90% year-over-year. On the balance sheet, it maintains a current ratio of 0.86x, a quick ratio of 0.79x, working capital of $-4.72M, a debt-to-equity ratio of -201.94x, a debt ratio of 1, an interest coverage ratio of -17.39x, free cash flow of $-23.41M (TTM), and net debt of $-26.27M. Figures sourced from SEC EDGAR.
- Market Cap
- $153.99M
- P/E TTM
- -6.56x
- EPS TTM
- $-0.62
- P/B TTM
- -905.80x
- ROE TTM
- 131.22%
- ROA TTM
- -120.41%
- Debt To Equity
- -201.94x
- Free Cash Flow TTM
- $-23.41M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is NRX Pharmaceuticals, Inc. in?
NRX Pharmaceuticals, Inc. (NRXP) operates in the Pharmaceutical Preparations industry.
What exchange does NRXP trade on?
NRX Pharmaceuticals, Inc. (NRXP) trades on the Nasdaq.
Where is NRX Pharmaceuticals, Inc. incorporated?
NRX Pharmaceuticals, Inc. is incorporated in DE.
When was NRX Pharmaceuticals, Inc. (NRXP)'s most recent SEC filing?
NRX Pharmaceuticals, Inc. (NRXP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is NRXP's market cap?
NRX Pharmaceuticals, Inc. (NRXP) has a market capitalization of $153.99M as of 2026-06-30.
What is NRXP's EPS (earnings per share)?
NRX Pharmaceuticals, Inc. (NRXP)'s trailing twelve month EPS is $-0.62 as of 2026-06-30.
What is NRXP's ROE (return on equity)?
NRX Pharmaceuticals, Inc. (NRXP)'s trailing twelve month Return on Equity (ROE) is 131.22% as of 2026-06-30.
What is NRXP's ROA (return on assets)?
NRX Pharmaceuticals, Inc. (NRXP)'s trailing twelve month Return on Assets (ROA) is -120.41% as of 2026-06-30.
What is NRXP's EV/EBITDA?
NRX Pharmaceuticals, Inc. (NRXP)'s trailing twelve month EV/EBITDA is -6.49x as of 2026-06-30.